|
1）Ito K, Suzuki H, Horie T, et al. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res. 2005; 22(10): 1559-77
|
|
|
|
2）Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol. 2012; 165(5): 1260-87
|
|
|
|
|
|
3）Marquez B, Van Bambeke F. ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions. Curr Drug Targets. 2011; 12(5): 600-20
|
|
|
|
|
|
4）DeGorter MK, Xia CQ, Yang JJ, et al. Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol. 2012; 52: 249-73
|
|
|
|
|
|
5）Veau C, Leroy C, Banide H, et al. Effect of chronic renal failure on the expression and function of rat intestinal P-glycoprotein in drug excretion. Nephrol Dial Transplant. 2001; 16(8): 1607-14
|
|
|
|
|
|
6）Reyes M, Benet LZ. Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics. J Pharm Sci. 2011; 100(9): 3831-42
|
|
|
|
|
|
7）Mutsaers HA, van den Heuvel LP, Ringens LH, et al. Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations. PLoS One. 2011; 6(4): e18438
|
|
|
|
|
|
8）Huang ZH, Murakami T, Okochi A, et al. Expression and function of P-glycoprotein in rats with glycerol-induced acute renal failure. Eur J Pharmacol. 2000; 406(3): 453-60
|
|
|
|
|
|
9）Deguchi T, Ohtsuki S, Otagiri M, et al. Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney. Kidney Int. 2002; 61(5): 1760-68
|
|
|
|
|
|
10）Naud J, Nolin TD, Leblond FA, et al. Current understanding of drug disposition in kidney disease. J Clin Pharmacol. 2012; 52(1 Suppl): 10S-22S
|
|
|
|
|
|
11）Naud J, Laurin LP, Michaud J, et al. Effects of chronic renal failure on brain drug transporters in rats. Drug Metab Dispos. 2012; 40(1): 39-46
|
|
|
|
|
|
12）Sekine T, Miyazaki H, Endou H. Molecular physiology of renal organic anion transporters. Am J Physiol Renal Physiol. 2006; 290(2): F251-61
|
|
|
|
|
|
13）Masereeuw R, Russel FG. Therapeutic implications of renal anionic drug transporters. Pharmacol Ther. 2010; 126(2): 200-16
|
|
|
|
|
|
14）Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther. 2006; 109(1-2): 1-11
|
|
|
|
|
|
15）Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008; 4(8): 1065-74
|
|
|
|
|
|
16）Toyohara T, Suzuki T, Morimoto R, et al. SL CO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J Am Soc Nephrol. 2009; 20(12): 2546-55
|
|
|
|
|
|
17）Ohtsuki S, Asaba H, Takanaga H, et al. Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J Neurochem. 2002; 83(1): 57-66
|
|
|
|
|
|
18）Enomoto A, Takeda M, Tojo A, et al. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol. 2002; 13(7): 1711-20
|
|
|
|
|
|
19）Enomoto A, Takeda M, Taki K, et al. Interactions of human organic anion as well as cation transporters with indoxyl sulfate. Eur J Pharmacol. 2003; 466(1-2): 13-20
|
|
|
|
|
|
20）Enomoto A, Niwa T. Roles of organic anion transporters in the progression of chronic renal failure. Ther Apher Dial. 2007; 11 Suppl 1: S27-31
|
|
|
|
|
|
21）Ji L, Masuda S, Saito H, et al. Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kidney Int. 2002; 62(2): 514-24
|
|
|
|
|
|
22）Aoyama I, Enomoto A, Niwa T. Effects of oral adsorbent on gene expression profile in uremic rat kidney: cDNA array analysis. Am J Kidney Dis. 2003; 41(3 Suppl 1): S8-14
|
|
|
|
|
|
23）Laouari D, Yang R, Veau C, et al. Two apical multidrug transporters, P-gp and MRP2, are differently altered in chronic renal failure. Am J Physiol Renal Physiol. 2001; 280(4): F636-45
|
|
|
|
|
|
24）Mikkaichi T, Suzuki T, Onogawa T, et al. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004; 101(10): 3569-74
|
|
|
|
|
|
25）Naud J, Michaud J, Beauchemin S, et al. Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats. Drug Metab Dispos. 2011; 39(8): 1363-9
|
|
|
|
|
|
26）Sakurai Y, Motohashi H, Ueo H, et al. Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res. 2004; 21(1): 61-7
|
|
|
|
|
|
27）Naud J, Michaud J, Leblond FA, et al. Effects of chronic renal failure on liver drug transporters. Drug Metab Dispos. 2008; 36(1): 124-8
|
|
|
|
|
|
28）Naud J, Michaud J, Boisvert C, et al. Down-regulation of intestinal drug transporters in chronic renal failure in rats. J Pharmacol Exp Ther. 2007; 320(3): 978-85
|
|
|
|
|
|
29）Teng S, Piquette-Miller M. Regulation of transporters by nuclear hormone receptors: implications during inflammation. Mol Pharm. 2008; 5(1): 67-76
|
|
|
|
|
|
30）Muntane J. Regulation of drug metabolism and transporters. Curr Drug Metab. 2009; 10(8): 932-45
|
|
|
|
|
|
31）Cressman AM, Petrovic V, Piquette-Miller M. Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response. Expert Rev Clin Pharmacol. 2012; 5(1): 69-89
|
|
|
|
|
|
32）Zyga S, Christopoulou G, Malliarou M. Malnutrition-inflammation-atherosclerosis syndrome in patients with end-stage renal disease. J Ren Care. 2011; 37(1): 12-5
|
|
|
|
|
|
33）Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int. 2005; 67(4): 1216-33
|
|
|
|
|
|
34）Svoboda M, Riha J, Wlcek K, et al. Organic anion transporting polypeptides (OATPs): regulation of expression and function. Curr Drug Metab. 2011; 12(2): 139-53
|
|
|
|
|
|
35）Teng S, Piquette-Miller M. The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice. J Pharmacol Exp Ther. 2005; 312(2): 841-8
|
|
|
|
|
|
36）Fang C, Yoon S, Tindberg N, et al. Hepatic expression of multiple acute phase proteins and down-regulation of nuclear receptors after acute endotoxin exposure. Biochem Pharmacol. 2004; 67(7): 1389-97
|
|
|
|
|
|
37）Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001; 276(18): 14581-7
|
|
|
|
|
|
38）Suzuki T, Toyohara T, Akiyama Y, et al. Transcriptional regulation of organic anion transporting polypeptide SLCO4C1 as a new therapeutic modality to prevent chronic kidney disease. J Pharm Sci. 2011; 100(9): 3696-707
|
|
|
|
|
|
39）Toyohara T, Akiyama Y, Suzuki T, et al. Metabolomic profiling of uremic solutes in CKD patients. Hypertens Res. 2010; 33(9): 944-52
|
|
|
|
|
40）Akiyama Y, Kikuchi K, Saigusa D, et al. Indoxyl sulfate down-regulates SLCO4C1 transporter through up-regulation of GATA3. PloS One. (in revision)
|
|
|
|
|